GLP-1 drugs and facial changes: what the science says

What did @terrikrishawn actually say?

The transcript here is fragmentary and hard to parse cleanly. The phrase "I like my bitch, repole, as fat as yellow, like slim, yellow" does not map to a coherent medical or lifestyle claim in its literal form. The caption, "Hello Cheekbones!", does the real communicating. The implication is clear enough: the creator is attributing visible facial changes, specifically more defined cheekbones, to weight loss, most likely from a GLP-1 medication given the category tag. That is the claim worth examining.

To be transparent with readers: when a transcript is this garbled, fact-checkers should be careful not to invent claims. What we can fact-check is the framing the caption establishes and what that framing gets right or wrong about GLP-1-related body composition changes.

Does the science back this up?

Yes, with a significant asterisk. GLP-1 receptor agonists do produce real, measurable fat loss, and facial fat is not exempt. But the specific experience varies considerably, and the "hello cheekbones" framing glosses over a phenomenon researchers are calling "Ozempic face."

A 2023 analysis in the Journal of the American Academy of Dermatology noted that rapid weight loss from GLP-1 medications can cause facial volume loss that goes beyond cheekbone definition, producing a gaunt or aged appearance that some patients find distressing. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed average body weight reductions of around 15 percent with semaglutide, which is significant enough to visibly reshape the face. Whether that reads as "cheekbones" or as hollowed temples depends on baseline fat distribution, age, skin elasticity, and rate of loss.

• GLP-1s reduce total body fat, including facial fat depots.
• Faster loss correlates with more noticeable facial changes.
• Not all of those changes are universally flattering.

What did they get wrong (or right)?

They got the basic reality right: GLP-1 medications do change facial appearance for many people, and cheekbone definition emerging from fat loss is a real and documented outcome. Credit where it is due.

What the video sidesteps is the full picture. "Hello Cheekbones!" is a celebration, which is fine, but it presents one possible outcome of facial fat loss as if it is the guaranteed one. Dermatologists including Dr. Paul Jarrod Frank have publicly discussed the volume loss and skin laxity that can accompany rapid GLP-1-driven weight loss, particularly in patients over 40. A study by Muñoz Morales et al. (2023, Aesthetic Surgery Journal) found that patients losing more than 10 percent of body weight rapidly were at elevated risk for facial deflation requiring filler correction. The video, understandably, does not mention any of that. It is a celebration post, not a medical briefing, but people making treatment decisions deserve the fuller version.

What should you actually know?

If you are on a GLP-1 medication and noticing facial changes, a few things are worth understanding before you post your "hello cheekbones" moment or, alternatively, panic about looking older.

First, facial fat loss is a real side effect of significant weight reduction on these medications. It is not unique to GLP-1s. It happens with any substantial weight loss. Second, the outcome depends heavily on how fast you lose, your age, and your baseline. Third, there are clinical strategies, including slower titration to reduce the rate of loss and, for some patients, facial filler or other interventions, that a licensed provider can discuss with you. Fourth, and worth saying plainly: the aesthetic outcome that looks like "hello cheekbones" in one person can look like facial wasting in another. Neither outcome is a failure. Both are worth knowing about before you start.

Talk to your prescribing clinician if you have concerns. Do not adjust your dose based on aesthetic goals alone.